Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02688517 · ClinicalTrials.gov registry record

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

A clinical trial of Malignant Neoplasm, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
1,100
Enrollment target
11
Study locations

NCT02688517 is a study of Malignant Neoplasm that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1,100 participants, above the 495-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (122% higher). The trial reports 11 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02688517, a study of Malignant Neoplasm, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
1,100 participants
Enrollment target
11
Study locations

Study Summary

This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.

Conditions Studied

Malignant Neoplasm

Interventions

  • OTHER Laboratory Biomarker Analysis
  • OTHER Cytology Specimen Collection Procedure

Study Locations (11)

New Jersey

  • Ocean Medical Center - Brick
  • Bayshore Community Hospital - Holmdel
  • RWJBarnabas Health - Jersey City Medical Center, Jersey City - Jersey City
  • Southern Ocean County Medical Center - Manahawkin
  • Morristown Medical Center - Morristown
  • Jersey Shore Medical Center - Neptune City
  • Rutgers Cancer Institute of New Jersey - New Brunswick
  • Riverview Medical Center/Booker Cancer Center - Red Bank
  • Riverview Medical Center - Red Bank
  • Overlook Hospital - Summit

Wisconsin

  • University of Wisconsin Hospital and Clinics - Madison

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2013-02
Est. Completion 2030-05

Sponsor

Rutgers, The State University of New Jersey

413 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02688517

The ClinicalTrials.gov registry entry for NCT02688517 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 495-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (122% higher). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02688517 reports 11 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT02688517 about?

NCT02688517 is a clinical study titled "Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer". This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in...

What is the current status of trial NCT02688517?

This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2013-02. Estimated completion is 2030-05.

What conditions does trial NCT02688517 study?

This clinical trial studies the following conditions: Malignant Neoplasm.

What interventions are being tested in trial NCT02688517?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).

Who is sponsoring clinical trial NCT02688517?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02688517 being conducted?

This trial has 11 study locations across New Jersey, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Neoplasm

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.